CA-DENODO
18.5.2021 09:02:11 CEST | Business Wire | Press release
Data virtualization leader Denodo’s fourth annual cloud usage survey finds organizations are accelerating their cloud journey to take advantage of its flexibility, control costs, speed time-to-market, and simplify data management. According to survey respondents, which included 150 global business and IT professionals from various industry sectors, hybrid-cloud deployment remains the dominant choice, as more than a third of these organizations (35 percent) use this model. Private cloud has shown some vibrant usage, accounting for almost a quarter of all workloads (24 percent), followed by public cloud, which remained almost flat at 16 percent. Multi-cloud remains a popular choice for almost one in ten organizations (9 percent) who opt to procure best of breed applications, data repositories, and infrastructure orchestration technologies among different cloud service providers to avoid a single vendor lock-in.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210518005232/en/
The complimentary findings are available for download here .
Even though the number of organizations with some level of cloud adoption remained steady year-over-year, the percentage of organizations that are moving advanced workloads to the cloud has increased by 25 percent (19.59 percent in 2021 vs. 15.48 percent in 2020). While security and skills are still major concerns for organizations, the statistics clearly indicates that businesses are becoming more confident about moving their important workloads to the cloud and embracing cloud more than ever. In terms of cloud providers, AWS and Azure still hold the lion’s share of the cloud market (65 percent combined), while others like Google Cloud Platform (GCP) are slowly catching up.
As a sizeable percentage of organizations are cautiously putting their first step into the cloud, Marketplaces are becoming very popular as almost half (45 percent) are leveraging them to take advantage of various incentives, including low upfront investments and risks. Utility/pay-as-you-go pricing is the most popular motivation at 35 percent followed by its self-service capability/ability to minimize IT dependency (25 percent), and simplified procurement (14 percent). Avoiding a long-term commitment was also a motivator at 6 percent.
Companies are using cloud for various use cases with the top two popular being analytics and infrastructure usage, and AI/ML. AI/ML and stream processing use cases are showcasing their importance on how businesses are using those technologies for their day-to-day operations, as year-over-year growth for each ranged between 50 and 100 percent. Close to 50 percent of participants leverage multiple solutions for data integration in the cloud, the most popular ones being data lakes, ETL pipeline, cloud data warehouse and object storage.
As organizations embrace cloud faster than ever, IT processes are becoming more automated and agile through the adoption of microservices and containers. Fifty percent of survey respondents indicated that they are using Docker for automation and portability. Kubernetes adoption is also increasing at a steady pace, because for many organizations, hundreds and at times thousands of microservices span both on-premises IT environments and multiple clouds.
“While we already know that cloud has become an inevitable force in IT infrastructure management, with cloud migration challenges abound, organizations often do not have a clear path to cloud adoption,” said Ravi Shankar, senior vice president and chief marketing officer of Denodo. “For the last four years, our audience has been sharing how they see the path to a successful infrastructure modernization unfolding. Just like majority of our audience, I personally believe that a well laid out logical data fabric, created with data virtualization, may be the key to helping organizations embrace a hybrid or multi-cloud strategy that is easy to deploy, manage, and maintain.”
Methodology:
The 2021 Denodo Global Cloud Study surveyed 150 organizations in March 2021. Users from various backgrounds, roles and regions participated. The full report is available for download here .
Please Tweet: New survey from #datavirtualization leader @denodo reveals advanced workloads moving to the #cloud as organizations embrace #hybrid and #multi-cloud architectures
About Denodo
Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210518005232/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
